Home › Cancro al rene (carcinoma a cellule renali) › Connecticut › New Haven
Studi clinici su Cancro al rene (carcinoma a cellule renali) a New Haven, CT
13 studi su Cancro al rene (carcinoma a cellule renali) cercano partecipanti presso sedi a New Haven e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
In reclutamentoFase 1
- NEO-811 Connecticut Site, New Haven
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
In reclutamentoFase 1
- Yale - New Haven Hospital, New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #62, New Haven
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
In reclutamentoFase 1/2
- Local Institution - 0117, New Haven
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
In reclutamentoFase 2
- Yale University Cancer Center LAO, New Haven
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
In reclutamentoFase 3
- Yale University, New Haven
- Smilow Cancer Hospital-Derby Care Center, Derby · a 8 mi di distanza
- Smilow Cancer Hospital Care Center - Guilford, Guilford · a 13 mi di distanza
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
In reclutamentoFase 1
- Xencor Investigative Site, New Haven
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
In reclutamentoFase 1/2
- Yale University Hospital, New Haven
Investigation of Lymph Node Biology in Kidney Cancer
In reclutamentoVolontari sani benvenuti
- Yale University, New Haven
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
In reclutamentoFase 1
- Yale University School of Medicine /ID# 225707, New Haven
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
In reclutamentoFase 1/2
- Yale School of Medicine, North Haven · a 7 mi di distanza
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
In reclutamentoFase 2
- Yale University, New Haven
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
In reclutamentoFase 1/2
- Yale Cancer Center, New Haven
Studi su Cancro al rene (carcinoma a cellule renali) in altre città
- Houston, TX35 studi
- New York City, NY27 studi
- Nashville, TN23 studi
- Dallas, TX23 studi
- St. Louis, MO23 studi
- Los Angeles, CA20 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Cleveland, OH14 studi
Altri studi a New Haven
- Cancro del polmone non a piccole cellule41 studi
- Cancro al seno38 studi
- Cancro (tutti i tipi)33 studi
- Cancro metastatico23 studi
- Cancro ai polmoni22 studi
- Carcinoma a cellule squamose della testa e del collo22 studi
- Cancro ovarico21 studi
- Cancro colorettale20 studi
- Cancro alla prostata20 studi
- Leucemia mieloide acuta17 studi
- Disturbo da uso di alcol (AUD)17 studi
- Overdose di oppioidi17 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.